Fas, Fas-associated death domain-like interleukin 1β-converting enzyme-like inhibitory protein, and apoptotic features of elderly acute myeloid leukemia based on response to induction chemotherapy

International Journal of Hematology

Volumn 82, Issue 4, 2005, Pages 327-332

  Kim, Hee Je ^a   Park, Byung Hee ^a   Choi, Young ^a   Min, Woo Sung ^a,b   Lee, Jong Wook ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Catholic Hemopoietic Stem Cell Transplantation Center   (South Korea)

Author keywords

Apoptotic responses; Elderly AML patients; FLIP molecule; Induction chemotherapy

Indexed keywords

7 AMINODACTINOMYCIN; ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYTARABINE; CYTOKINE; ETOPOSIDE; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOCORTIN 5; MESSENGER RNA; METHOTREXATE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGING; APOPTOSIS; ARTICLE; BLOOD SMEAR; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INFECTION; LUNG ABSCESS; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PANCYTOPENIA; PNEUMOCYSTOSIS; PNEUMONIA; PROGNOSIS; PSYCHOSIS; SEPSIS;

AGED; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOCYTIC, ACUTE; POLYMERASE CHAIN REACTION; PROBABILITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; SURVIVORS;

EID: 33644682975     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A30503     Document Type: Article

References (32)

1. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkable distinct response to standard chemotherapy-a Southwest Oncology Group study. Blood. 1997;89:3323-3329.
2. Leith CP, Chen I, Kopecky KJ. Correlation of multidrug resistance (MDR1) protein expression with functional Dye/Drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant/MDR-/Efflux+- and MDR1+/Efflux- cases. Blood. 1995;86:2329-2342.
3. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 1995;9:1491-1498.
4. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognostic despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112:118-126.
5. Hamblin TJ. The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome. Leukemia Res. 1992;16:4101-4108.
6. Hoyle CF, de Bastos M, Wheatley K, et al. AML associated with previously cytotoxic therapy, MDS or myelo-proliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989;72:45-53.
7. Nussler V, Saver H, Pelka-Fleischerf R, Holzel D, Wilmanns W. Clinical biochemical and cytotoxic parameters for distinguishing smouldering and rapidly proliferating variants of acute leukaemia. Eur J Hematol. 1990;45:19-25.
8. Howe RB, Bloomfield CD, McKenna RW. Hypocellular acute leukaemia. Am J Med. 1982;72:391-395.
9. Buchner T, Urbanitz D, Hiddenmann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol. 1985;3:1583-1589.
10. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
11. Buchner T, Hiddemann W, Schaefer UW, et al. Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML. Leukemia. 1992;6(suppl 4):68-70.
12. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98:548-553.
13. Stone RM, Berg TB, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995;332:1671-1677.
14. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med. 1995;332:1678-1683.
15. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60:454-462.
16. Detourmignies L, Wattel E, Lai JL, Bauters F, Fenaux P. Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? Ann Hematol. 1993;66:235-240.
17. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first remission. J Clin Oncol. 2001;19:3244-3254.
18. Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001;98:241-243.
19. Schittenhelm M, Aichele O, Krober SM, Brummendorf T, Kanz L, Denzlinger C. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571). Leuk Lymphoma. 2003;44:1251-1253.
20. Dorr R, Karanes C, Spier C, et al. Phase I/II study of the p-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 2001;19:1589-1599.
21. McSweeney PA, Niederwiesesr D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
22. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480-1484.
23. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone vs daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukaemia in the elderly: final report. European Organization of the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16:872-881.
24. Kim HJ, Whartenby KA, Georgantas RW, Wingard J, Civin CI. Human CD34+ cells are resistant to FasL due to high expression of FLIP. Stem Cells. 2002;20:174-182.
25. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia: a randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia Group. J Clin Oncol. 1989;7:1268-1274.
26. Foon KA, Zighelboim J, Yale C, Gale RP. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukaemia. Blood. 1981;3:467-470.
27. Godwin JE, Smith SE. Acute myeloid leukemia in the older patient. Cut Rev Oncol Hematol. 2003;48S:S17-S26.
28. Lewis NR, Pallis M, Russell NH. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia. Exp Hematol. 2000;28:535-542.
29. Gupta P, Niehans GA, LeRoy SC, et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia. 1999;13:44-53.
30. Komada Y, Sakurai M. Fas receptor (CD95)-mediated apoptosis in leukemic cells. Leuk Lymphoma. 1997;25:9-21.
31. Braess J, Schneiderat P, Schoch C, Fiegl M, Lorenz I, Hiddemann W. Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response. Br J Haematol. 2004;126:338-347.
32. + subpopulation of leukemia cells. Leukemia. 2003;17:2130-2139.